Top global biopharmas witness 6% growth in market capitalization in 1st-qtr 2025

23 April 2025

The biopharmaceutical industry saw a strong start to 2025, despite ongoing uncertainty around the potential impact of US President Donald Trump’s proposed pharmaceutical tariffs impacting global supply chains.

Nevertheless, the industry remains resilient, with the top 20 biopharmaceutical companies reporting an upturn of 6% in aggregate market capitalization from $3.7 trillion as on December 31, 2024 to $3.9 trillion as on March 31, 2025, reveals pharma analytics company GlobalData.

Ophelia Chan, senior business fundamentals analyst at GlobalData, noted that two-thirds, 13 of the top 20 biopharmaceutical companies reported growth in market capitalization, with 10 companies, including Vertex Pharmaceuticals (Nasdaq: VRTX) +22%, Gilead Sciences (Nasdaq GILD) +21.1%, Roche (ROG: SIX) +18.5%, Amgen (Nasdaq: AMGN) +17.7%, and AbbVie (NYSE: ABBV) +15.6%, registering more than 15% market capitalization growth, as per GlobalData’s Companies Database Pharma Intelligence Center.”

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK